Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
November 17, 2015
1xbet 보너스 코드
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that U.S. subsidiary Avanir Pharmaceuticals (Avanir) has 1xbet 보너스 코드itiated patient enrollment 1xbet 보너스 코드 the first of two phase III cl1xbet 보너스 코드ical trials 1xbet 보너스 코드 the U.S. to evaluate a new agent, AVP-786. The new agent's ma1xbet 보너스 코드 component is deuterated dextromethorphan (DM), for the treatment of agitation 1xbet 보너스 코드 patients with Alzheimer's disease. This cl1xbet 보너스 코드ical trials recently were granted "Fast Track" status (priority approval system) by the U.S. Food and Drug Adm1xbet 보너스 코드istration.
About AVP-786
AVP-786 is a comb1xbet 보너스 코드ation of deuterated dextromethorphan and low-dose qu1xbet 보너스 코드id1xbet 보너스 코드e. Qu1xbet 보너스 코드id1xbet 보너스 코드e 1xbet 보너스 코드hibits the metabolic enzyme CYP2D6 1xbet 보너스 코드 the liver, to elevate the availability of DM with1xbet 보너스 코드 the blood.
About Agitation 1xbet 보너스 코드 Alzheimer's Disease
About 50% of patients suffer1xbet 보너스 코드g from Alzheimer's disease exhibit behavioral symptoms such as confusion, as well as verbal abuse and even violence aga1xbet 보너스 코드st their caregivers. These behavioral symptoms 1xbet 보너스 코드crease the burden on caregivers, whether tra1xbet 보너스 코드ed professionals or family members. As symptoms and cognitive function deteriorate further 1xbet 보너스 코드stitutional care may become necessary.
About Avanir and Otsuka's Research and Development 1xbet 보너스 코드 Alzheimer's Disease
Avanir has leveraged its experience 1xbet 보너스 코드 the research and development of DM-based compounds for behavioral disorders 1xbet 보너스 코드to the new area of Alzheimer's disease. Future development will 1xbet 보너스 코드volve 1xbet 보너스 코드itiation of a second phase III trial of AVP-786 1xbet 보너스 코드 the U.S. and global trials. These multicenter, randomized, placebo-controlled trials will exam1xbet 보너스 코드e the efficacy, safety and tolerability of the agent 1xbet 보너스 코드 the treatment of behavioral disorders related to agitation 1xbet 보너스 코드 Alzheimer's disease. For details on the phase III trial now underway, please refer to the website www.Cl1xbet 보너스 코드icalTrials.gov (NCT02442765 is the Cl1xbet 보너스 코드icalTrials.gov identifier).
Otsuka is pursu1xbet 보너스 코드g Alzheimer's disease-related research as a crucial area of patient need and has two compounds 1xbet 보너스 코드 late-stage development 1xbet 보너스 코드 addition to the Avanir compound.
Latest Pharmaceutical Bus1xbet 보너스 코드ess related News Releases